SCHEMBL6085573

SCHEMBL6085573

Cc1ccc(C(C)C)c2oc(-c3c[nH]nc3-c3cccc(NS(=O)(=O)Cc4ccccc4)c3)nc12

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.42
PTPN2 P17706 1/20 0.38
PTPN1 P18031 1/20 0.38
PTPN5 P54829 1/20 0.38
SYK P43405 1/20 0.37
TTK P33981 1/20 0.35
BRAF P15056 1/20 0.35
ALDH1A1 P00352 3/20 0.34
HPGD P15428 3/20 0.34
KDM4E B2RXH2 1/20 0.34
PTGER1 P34995 1/20 0.34
CYP19A1 P11511 1/20 0.34
LMNA P02545 1/20 0.34
HSP90AA1 P07900 1/20 0.34
THRB P10828 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
CYP17A1 P05093 1/20 0.34
MAP3K5 Q99683 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6086910 0.92 HSP90AA1 (0.39) BRD4ALDH1A1HPGDLMNAHSP90AA1
SCHEMBL6085567 0.85 PTPN2 (0.42) PTPN2PTPN1PTPN5ALDH1A1HPGD
SCHEMBL6203053 0.85 PTPN2 (0.42) PTPN2PTPN1PTPN5ALDH1A1HPGD
SCHEMBL6084819 0.82 ALDH1A1 (0.44) ALDH1A1HPGDKDM4ELMNANPSR1
SCHEMBL6085797 0.82 NPC1 (0.42) TTKALDH1A1HPGDKDM4E
SCHEMBL6084903 0.80 MEN1 (0.44) ALDH1A1HPGDKDM4ELMNANPSR1
SCHEMBL6085450 0.78 PTPN2 (0.56) BRD4PTPN2PTPN1PTPN5ALDH1A1
SCHEMBL6084209 0.78 PTPN2 (0.49) BRD4PTPN2PTPN1PTPN5SYK
SCHEMBL6085294 0.78 PTPN2 (0.56) BRD4PTPN2PTPN1PTPN5ALDH1A1
SCHEMBL6086056 0.77 POLB (0.44) ALDH1A1HPGDLMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US claimed
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US disclosed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP disclosed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors MAP3K15, MAP3K20, MAP3K3 BRD4 725/4885PTPN2 370/4885PTPN1 344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.